Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

100 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Evotec SE, Nine Months 2023 Earnings Call, Nov 08, 2023
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
PR
Flagship Pioneering Announces Appointment of Rupert Vessey as Chief Scientist
AQ
Transcript : Bristol-Myers Squibb Company, Q4 2022 Earnings Call, Feb 02, 2023
BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
Bristol-Myers Squibb Company Announces Resignation of Dr. Rupert Vessey, Executive Vice President, Research and Early Development, Effective July 3, 2023
CI
BIO-TECHNE CORP : Results of Operations and Financial Condition, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Immatics N : and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs - Form 6-K
PU
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BU
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
GL
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
AQ
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
GL
Transcript : Bristol-Myers Squibb Company Presents at Guggenheim Healthcare Talks | Targeted Protein Degradation Day, Mar-16-2022 10:15 AM
Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16
BU
Alexandria Real Estate Equities, Inc. Announces Long-Term Lease With Bristol Myers Squibb for a New 427,000 RSF Innovative Research Hub at the Alexandria Point Mega Campus in the San Diego Cluster Market
PR
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
PR
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BU
Transcript : Bristol-Myers Squibb Company - Analyst/Investor Day
Press Release dated November 12, 2021 – “Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021” - Form 6-K
PU
Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
PR
BIO-TECHNE CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Nereid Therapeutics : Announces Appointments of Laura Forese and Rupert Vessey to Its Board of Directors
PR
Transcript : Bio-Techne Corporation - Analyst/Investor Day
Bristol Myers Squibb Exercises Option to Develop Exscientia’s AI-designed, Immune-modulating Drug Candidate
BU
Exscientia : announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb
BU
Evotec : launches 'beLAB1407' to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb
AQ
Evotec : launches 'beLAB1407' to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb
EQ
Transcript : Bristol-Myers Squibb Company - Shareholder/Analyst Call
Evotec : launches 'beLAB2122', translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb
AQ
Evotec : launches “beLAB2122”, translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb
PU
Evotec : launches 'beLAB2122', translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb
EQ
Bristol Myers Squibb : Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in Chemistry
BU
Bristol Myers Squibb : Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb
BU
BIO-TECHNE CORP : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Bristol Myers Squibb : UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026
AQ
UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026
GL
Bristol Myers Squibb : UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026
BU
Bristol Myers Squibb : Completes Acquisition of Forbius
AQ
Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases
BU
Bristol Myers Squibb : Completes Acquisition of Forbius
BU
Obsidian Therapeutics : Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate
PR
Bio Techne : Annual Report FY 2020
PU
Transcript : Bristol-Myers Squibb Company Presents at Citi 15th Annual Biopharma Virtual Conference 2020, Sep-08-2020 12:15 PM
Bristol Myers Squibb : to Participate in Citi’s 15th Annual BioPharma Virtual Conference
BU
Bristol Myers Squibb : Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
BU
Bristol Myers Squibb : Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program
BU
Transcript : Bristol-Myers Squibb Company - Special Call
Transcript : Bristol-Myers Squibb Company - Special Call
Transcript : Bristol-Myers Squibb Company - Special Call
Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb
BU
No results for this search
  1. Stock Market
  2. Advanced search
  3. Rupert Vessey
  4. News